EMA Authorised: Veyvondi (vonicog alfa) — Baxalta Innovations GmbH

View source ↗

Summary

EMA authorised Veyvondi (vonicog alfa) by Baxalta Innovations GmbH for von Willebrand diseases.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Von Willebrand Disease

Drugs mentioned

• Veyvondi (vonicog alfa)

Snippet

Status: Authorised. Therapeutic area: von Willebrand Diseases. MAH: Baxalta Innovations GmbH. Decision date: 18/12/2025